| 1994 |
- YM BioSciences Inc. established in Canada.
|
| 1995-1996 |
- Initial financing ($2.5 million)* and in-licensing of nimotuzumab.
|
| 1997 |
- First external financing ($14.5 million).
|
| 2000 |
- Raised $17.5 million to expand geographic and product diversification.
- Acquired tesmilifene and Norelin.
|
| 2002 |
- Initial Public Offering of $15 million on AIM (London Stock Exchange) and TSX (Toronto Stock Exchange).
|
| 2003 |
- Out-licensed nimotuzumab in Europe (Oncoscience AG).
- Completed first financing (PIPE) for C$19 million.
- Received Special Protocol Assessment (SPA) for tesmilifene from the FDA.
|
| 2004 |
- Initiated international pivotal breast cancer study with tesmilifene.
- C$20 million Bought-Deal marketed in US.
- Listed on AMEX (American Stock Exchange) October 1.
|
| 2005 |
- Out-licensed tesmilifene in Korea (Shin Poong Pharmaceutical Co., Ltd.).
- Acquired DELEX Therapeutics Inc. and AeroLEF®.
- Recruitment of tesmilifene pivotal trial completed in September.
- Out-licensed nimotuzumab in Korea (Kuhnil Pharmaceutical Co., Ltd.) and South East Asia (Innogene Kalbiotech Pte., Ltd.).
|
| 2006 |
- US$40 million Registered Direct in US.
- Acquired Eximias Pharmaceutical Corporation and established YM BioSciences USA.
- Treasury Department clears nimotuzumab for importation into US for clinical trials.
- Out-licensed nimotuzumab in Japan (Daiichi-Sankyo Co., Ltd.).
|
| 2007 |
- Completion of first randomized trial for AeroLEF, successful achievement of primary and secondary endpoints and first IND clearance from FDA.
- Nimotuzumab cleared for clinical trials in Canada in children with inoperable brain cancer and adult colorectal cancer.
|
| 2009 |
- Nimotuzumab cleared for clinical trials in Canada and internationally in patients with non-small cell lung cancer and brain metastases from lung cancer.
|
| 2010 |
- Nimotuzumab cleared for clinical trials in the US in patients with non-small cell lung cancer and brain metastases from lung cancer.
- Acquired Cytopia Limited and established YM BioSciences Australia Ltd.
- Acquired CYT387 and CYT997.
|
